<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04202835</url>
  </required_header>
  <id_info>
    <org_study_id>CTTC1901</org_study_id>
    <secondary_id>OZM-099</secondary_id>
    <nct_id>NCT04202835</nct_id>
  </id_info>
  <brief_title>ATG Plus PTCy vs ATG for CGVHD Prophylaxis</brief_title>
  <official_title>A Randomized Pilot Trial Comparing Anti-Thymocyte Globulin (ATG) With ATG Plus Post Transplant Cyclophosphamide (PTCy) for Prophylaxis Against Acute and Chronic Graft Versus Host Disease (GVHD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>McMaster University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Cell Therapy Transplant Canada</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ozmosis Research Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>McMaster University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Randomized Pilot Trial to test the feasibility of comparing anti-thymocyte globulin plus&#xD;
      post transplant cyclophosphamide with anti-thymocyte globulin alone to prevent chronic graft&#xD;
      versus host disease.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with acute leukemia or myelodysplastic syndrome will be randomized to receive, or&#xD;
      not receive, post transplant cyclophosphamide in addition to anti-thymocyte globulin.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 13, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2024</completion_date>
  <primary_completion_date type="Anticipated">October 13, 2024</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomized pilot trial</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Registration of 80 patients within twenty four months</measure>
    <time_frame>24 months</time_frame>
    <description>Registration will be documented by the Clinical Research Organization (Ozmosis Research Inc.)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>CRFS</measure>
    <time_frame>27 months</time_frame>
    <description>Chronic graft versus host disease free- and relapse-free survival (CRFS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GRFS</measure>
    <time_frame>27 months</time_frame>
    <description>Graft versus host disease-, and relapse-, free survival (GRFS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Survival</measure>
    <time_frame>27 months</time_frame>
    <description>Survival (dead/alive) at 100 days for each patient</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complete data collection</measure>
    <time_frame>27 months</time_frame>
    <description>The Clinical Research Organization (Ozmosis Research Inc.) will document completeness of data collection</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cost of study</measure>
    <time_frame>27 months</time_frame>
    <description>The sponsor (McMaster University) and the Clinical Research Organization (Ozmosis Research Inc.) will compare actual total trial costs in Canadian dollars at trial completion (at completion of outcomes analysis and report) with expected costs as determined for the trial budget.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Acute Leukemia</condition>
  <condition>Myelodysplasia</condition>
  <condition>Chronic Graft-versus-host-disease</condition>
  <arm_group>
    <arm_group_label>ATG/PTCy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Anti-Thymocyte Globulin (ATG, Thymoglobulin) 4.5 mg/kg IV (divided 0.5, 2.0, 2.0 mg/kg on days -2, -1 and +1); cyclophosphamide (Post Transplant Cyclophosphamide, PTCy) 50 mg/kg IV daily on days +3 and +4.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ATG</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Anti-Thymocyte Globulin (ATG, Thymoglobulin) 4.5 mg/kg IV (divided 0.5, 2.0, 2.0 mg/kg on days -2, -1 and +1).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>Post Transplant Cyclophosphamide</description>
    <arm_group_label>ATG/PTCy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Anti-Thymocyte globulin (rabbit)</intervention_name>
    <description>Anti-Thymocyte Globulin (rabbit, Thymoglobulin)</description>
    <arm_group_label>ATG</arm_group_label>
    <arm_group_label>ATG/PTCy</arm_group_label>
    <other_name>Thymoglobulin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. The participant is aged ≥ 16 and deemed medically fit per investigator for protocol&#xD;
&#xD;
          2. The participant has either acute myeloid leukemia in 1st or 2nd complete remission&#xD;
             (CR), or has myelodysplastic syndrome&#xD;
&#xD;
          3. The participant will receive a blood progenitor cell graft (&quot;HPC, Apheresis&quot;)&#xD;
&#xD;
          4. The participant has a related or unrelated donor, who is fully MHC matched with the&#xD;
             recipient at HLA-A, B, C and DRB1.&#xD;
&#xD;
          5. The participant meets the transplant centre's criteria for transplantation, using&#xD;
             either myeloablative or reduced intensity conditioning.&#xD;
&#xD;
          6. The participant has good performance status (Karnofsky ≥60%)&#xD;
&#xD;
          7. The participant is able to understand and sign the informed consent form&#xD;
&#xD;
          8. Ability and willingness to comply with study procedures and schedule, in the&#xD;
             Investigator's opinion.&#xD;
&#xD;
          9. The participant is receiving their first transplant&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. The participant is HIV antibody positive&#xD;
&#xD;
          2. The participant has a hypersensitivity to rabbit proteins or Thymoglobulin®&#xD;
             pharmaceutical excipients, glycine or mannitol.&#xD;
&#xD;
          3. The participant has active or chronic infection (i.e. infection requiring oral or IV&#xD;
             therapy)&#xD;
&#xD;
          4. The participant (if female and of childbearing potential) is pregnant or&#xD;
             breast-feeding at the time of enrollment&#xD;
&#xD;
          5. The participant (if female and of childbearing potential) does not agree to use an&#xD;
             adequate contraceptive method from the time of enrollment until a minimum of one year&#xD;
             following transplant3&#xD;
&#xD;
          6. The participant (if male and fertile) does not agree to use an adequate contraceptive&#xD;
             method from the time of enrollment until a minimum of one year following transplant3&#xD;
&#xD;
          7. The participant has urinary outflow obstruction&#xD;
&#xD;
          8. The participant is in poor condition (determined per institutional guidelines)&#xD;
&#xD;
          9. The participant has acute leukemia in relapse&#xD;
&#xD;
         10. The participant has myelodysplastic syndrome with &gt; 10% marrow blasts&#xD;
&#xD;
         11. The participant is having their second transplant&#xD;
&#xD;
         12. The participant is taking T-cell antibody prophylaxis (anti-CD52)&#xD;
&#xD;
         13. The participant is receiving a cord blood graft or T-cell depleted grafts&#xD;
&#xD;
         14. The participant has mixed phenotype acute leukemia&#xD;
&#xD;
         15. The participant has prior malignancies, except resected nonmelanoma or treated&#xD;
             cervical carcinoma in situ. Cancer treated with curative intent ≥ 5 years previously&#xD;
             will be allowed. Cancer treated with curative intent &lt; 5 years previously must be&#xD;
             reviewed and approved by the sponsors.&#xD;
&#xD;
         16. The participant is in complete remission with incomplete recovery (CRi)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Irwin R Walker, MBBS</last_name>
    <role>Principal Investigator</role>
    <affiliation>McMaster University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Kristjan Paulson, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CancerCare Manitoba</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ayushi Sharma, CCRP</last_name>
    <phone>1 416 634 8310</phone>
    <email>ayushi.sharma@ozmosisresearch.ca</email>
  </overall_contact>
  <location>
    <facility>
      <name>Kinghorn Cancer Centre, St Vincent's Health Network</name>
      <address>
        <city>Darlinghurst</city>
        <state>New South Wales</state>
        <zip>2010</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Louise Christophersen</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Royal North Shore Hospital</name>
      <address>
        <city>St. Leonards</city>
        <state>New South Wales</state>
        <zip>2065</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Molly Forbes</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Australasian Leukaemia and Lymphoma Group</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3121</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nada Hamad, MBBS MSc</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CancerCare Manitoba</name>
      <address>
        <city>Winnipeg</city>
        <state>Manitoba</state>
        <zip>R3E 0V9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kristjan Paulson, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Queen Elizabeth II Health Sciences Centre</name>
      <address>
        <city>Halifax</city>
        <state>Nova Scotia</state>
        <zip>B3H 2Y9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mahmoud Elsawy, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Juravinski Hospital and Cancer Centre</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8V 1C3</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Irwin Walker, MBBS</last_name>
      <phone>905 521 2100</phone>
      <phone_ext>76384</phone_ext>
      <email>walkeri@mcmaster.ca</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>London Health Sciences Centre</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 5W9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Uday Deotare, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital de l'Enfant-Jésus</name>
      <address>
        <city>Québec City</city>
        <state>Quebec</state>
        <zip>G1R 2J6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Genevieve Gallagher, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Saskatchewan Cancer Agency</name>
      <address>
        <city>Saskatoon</city>
        <state>Saskatchewan</state>
        <zip>S7N 4H4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mohamed Elemary, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Canada</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>November 29, 2019</study_first_submitted>
  <study_first_submitted_qc>December 17, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 18, 2019</study_first_posted>
  <last_update_submitted>August 30, 2021</last_update_submitted>
  <last_update_submitted_qc>August 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 31, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>post transplant cyclophosphamide</keyword>
  <keyword>anti-thymocyte globulin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Graft vs Host Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Thymoglobulin</mesh_term>
    <mesh_term>Antilymphocyte Serum</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

